Treatment of Chronic Spontaneous Urticaria With Benralizumab: Report of Primary Endpoint Per Protocol Analysis, and Exploratory Endpoints

Bernstein, Jonathan A.; Singh, Umesh; Rao, Marepalli B.; Berendts, Karen; Zhang, Xiang; Mutasim, Diya F.

doi:10.22541/au.160382473.35466121/v1

Cited by 5 publications

(10 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Some well‐described targets are IL‐4 and IL‐13, which promote IgE production and infiltration of eosinophils, and IL‐5, which promotes survival of eosinophils 59 . Biologicals have been used in various inflammatory conditions such as eosinophilic asthma, 60,61 allergic rhinitis, 62 urticaria 63,64 and atopic dermatitis, 65,66 which have overlapping pathophysiology with type 2 CRS. This list of diseases did not include CRS until the recent completion of large multicentre phase III trials (Figure 3).…”

Section: Biologicalsmentioning

confidence: 99%

Highlights in the advances of chronic rhinosinusitis

Reitsma

Wang

et al. 2021

Allergy

View full text Add to dashboard Cite

Chronic rhinosinusitis (CRS) is a protracted inflammatory condition with global societal and financial burden. [1][2][3] Its prevalence is estimated to be 10-28% based on self-reported symptoms alone, 4,5 and about 4-9% when endoscopy 6 or imaging is applied. 7,8 Real world data suggest that nearly half of CRS patients have uncontrolled disease based on visual analogue scale for rhinosinusitis. 9 This subgroup has significant disease burden as these patients require longterm follow-up, medication and often repeat sinus surgeries. 10 Traditionally, CRS is classified based on the presence or absence of nasal polyps. It is evident that this classification based on a visual trait is probably an overly simplistic representation of a heterogenous condition with a spectrum of clinical presentations and severity. Hence in recent years, there is increasing interest in uncovering the inflammatory mechanisms, or endotypes, of CRS. With the advent of novel treatment options, including biologicals, the ability to accurately define endotypes and predict response to specific treatments via biomarkers is important in order to provide individualised patient care. 11 Research in CRS is a continually evolving field. The objective of this review is to update readers on the recent, important developments in the field of CRS in adults. This includes the changes in the latest edition of the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS2020), novel biomarkers, biologicals in the treatment of CRSwNP and the implications of the COVID-19 on the

show abstract

Section: Biologicalsmentioning

confidence: 99%

Highlights in the advances of chronic rhinosinusitis

Reitsma

Wang

et al. 2021

Allergy

View full text Add to dashboard Cite

show abstract

“…Mepolizumab and reslizumab have been successfully used in the treatment of individual patients with CSU 98,99 . Positive results of smaller controlled trials with benralizumab were recently published 100,101 . Benralizumab and mepolizumab are currently in clinical trials to test their efficacy in CSU (NCT04612725 and NCT03494881).…”

Section: Other Biologicals and Small Molecules Tested For Csumentioning

confidence: 99%

EAACI Biologicals Guidelines—Omalizumab for the treatment of chronic spontaneous urticaria in adults and in the paediatric population 12–17 years old

Agache

Akdiş

Brockow

et al. 2021

Allergy

View full text Add to dashboard Cite

Chronic spontaneous urticaria (CSU) imposes a significant burden on patients, families and healthcare systems. Management is difficult, due to disease heterogeneity and insufficient efficacy of classical drugs such as H 1 R-antihistamines. Better understanding of the mechanisms has enabled a stratified approach to the management of CSU, supporting the use of targeted treatment with omalizumab. However, many practical issues including selection of responders, the definition of response, strategies to enhance the responder rate, the duration of treatment and its regimen (in the clinic or home-based) and its cost-effectiveness still require further clarification. The EAACI Guidelines on the use of omalizumab in CSU follow the GRADE approach in formulating recommendations for each outcome. In addition, future therapeutic approaches and perspectives as well as research priorities are discussed.

show abstract

“…1 The rationale for using targeted therapy against IL-5 in CSU is the eosinophilic infiltrates and the presence of IL-5 in CSU hives, suggesting that IL-5 plays a role in the pathophysiology of CSU. 1,2,3 Here, we report a patient with CSU and concurrent severe eosinophilic asthma in whom benralizumab exacerbated CSU. Type I hypersensitivity to benralizumab was ruled out by a negative skin prick and intradermal test.…”

Section: Introductionmentioning

confidence: 99%

“…The anti-interleukin-5 monoclonal IL-5-(IL-5) receptor-α antibody benralizumab is currently proposed as one of the drugs for the treatment of patients with severe chronic spontaneous urticaria (CSU). 1 The rationale for using targeted therapy against IL-5 in CSU is the eosinophilic infiltrates and the presence of IL-5 in CSU hives, suggesting that IL-5 plays a role in the pathophysiology of CSU. 1,2,3 Here, we report a patient with CSU and concurrent severe eosinophilic asthma in whom benralizumab exacerbated CSU.…”

Section: Introductionmentioning

confidence: 99%